SynthesisOncotarget2017
CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications.Cancers · 2026Review
- CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.Scientific reports · 2026Article
- Glycosylation in Cancer.Handbook of experimental pharmacology · 2025Review
- The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer.International journal of molecular sciences · 2023Review
- The clinical significance of CD44v6 in malignant and benign primary bone tumors.BMC musculoskeletal disorders · 2023Article
- The prognostic value and immunological role of CD44 in pan-cancer study.Scientific reports · 2023Article
- CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.Frontiers in immunology · 2023Article
- PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.International journal of molecular sciences · 2022Article
- Article
- Membranous CD44v6 is upregulated as an early event in colorectal cancer: Downregulation is associated with circulating tumor cells and poor prognosis.Oncology letters · 2021Article
- Article
- CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients.Biomedicines · 2021Article
- The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer.Journal of cancer research and clinical oncology · 2020Article
- Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells.Cancers · 2020Article
- Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines.Theranostics · 2020Article
- CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity.Oncoimmunology · 2020Article
- CD44v6 engages in colorectal cancer progression.Cell death & disease · 2019Review
- AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer.JCI insight · 2018Article
- Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD44v6 has recently been reported as a biomarker for colorectal cancer. However, the clinical and prognostic significance of CD44v6 in colorectal cancer remains controversial. Therefore, we performed a meta-analysis to clarify this issue. A comprehensive literature search was performed using Medline, Embase and Web of Science, and the statistical analysis was conducted using Stata software. A total of twenty-one studies including 3918 colorectal cancer cases were included. The pooled analysis showed that CD44v6 overexpression in colorectal cancer was an independent prognostic marker correlating with lower 5-year overall survival rate (OR=0.78, 95%CI =0.67-0.91, p=0.001). CD44v6 overexpression was also associated with more lymph node invasion (OR=1.48, 95%CI= 1.02-2.15, p=0.04), and advanced Dukes stage (OR=2.47, 95%CI= 1.29-4.73, p=0.01). In addition, while excluding Zolbec's study, CD44v6 overexpression was associated with distance metastasis (OR=1.65, 95%CI =1.13-2.40, p=0.01). Taken together, this meta-analysis suggested that CD44v6 is an efficient prognostic factor in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.